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Abstract: Endometrial cancer is the most common gynecologic malignancy in industrialized countries.
Most patients are cured by surgery; however, about 15% of the patients develop recurrence with
limited treatment options. Patient-derived tumor xenograft (PDX) mouse models represent useful
tools for preclinical evaluation of new therapies and biomarker identification. Preclinical imaging
by magnetic resonance imaging (MRI), positron emission tomography-computed tomography
(PET-CT), single-photon emission computed tomography (SPECT) and optical imaging during
disease progression enables visualization and quantification of functional tumor characteristics,
which may serve as imaging biomarkers guiding targeted therapies. A critical question, however,
is whether the in vivo model systems mimic the disease setting in patients to such an extent that
the imaging biomarkers may be translatable to the clinic. The primary objective of this review is
to give an overview of current and novel preclinical imaging methods relevant for endometrial
cancer animal models. Furthermore, we highlight how these advanced imaging methods depict
pathogenic mechanisms important for tumor progression that represent potential targets for treatment
in endometrial cancer.
Keywords: preclinical imaging; imaging biomarkers; PDX models; mouse models; gynecological
cancer; endometrial cancer; positron emission tomography; magnetic resonance imaging; computed
tomography; optical imaging
1. Introduction
Endometrial cancer (EC) is the most common gynecologic malignancy in industrialized countries
and the incidence is increasing [1,2]. Most patients present with early-stage disease and are cured by
surgery; however, about 15% develop recurrence with limited treatment options and poor survival [3,4].
Although the identification of different genetic alterations has defined specific molecular subtypes
with potential for more individualized therapy in EC, the clinical treatment mostly remains the same
across molecular subtypes [4,5].
New, promising therapeutics based on preclinical models frequently fail to produce similar effects
in clinical trials. This may be related to poor preclinical model systems such as immortalized cell lines
implanted subcutaneously in mice, thus lacking metastatic potential and immediate relevance for the
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human setting. However, during the last decade preclinical cancer models have advanced with the
introduction of orthotopic models (tumor cells implanted in the organ of origin) and patient-derived
tumor xenograft (PDX) models, both putatively more translatable and transferable to the clinic.
Orthotopic PDX models have shown to mimic various human cancers in terms of histopathologic
characteristics, genetic- and molecular alterations, metastatic potential and therapeutic response [6].
Animal models for the most common types of gynecologic cancers have been developed, including
PDX of endometrial, cervical and ovarian cancer [7–9].
Monitoring intraabdominal gynecologic tumor growth is challenging and requires an advanced
imaging system. Traditionally, it required sacrificing a large number of animals for various ex vivo
assays and endpoint measurement of tumor size. These measurements derived from the same time
point (at sacrifice) inherently provide only static tumor information not capturing the dynamically
changing and interactive cascade of signaling events that induce tumor progression. Additionally,
during therapeutic intervention some molecularly targeted drugs may yield effect without reducing the
tumor volume [10] and this effect will consequently not be detected using this approach. Importantly,
robust and valid imaging biomarkers for early prediction of treatment response prior to detectable
tumor size reduction, may open the avenue for early tailoring of more individualized treatment
strategies in cancer.
The use of small-animal imaging in cancer research has increased over the last decade, especially
as the development of non-invasive advanced functional imaging techniques has allowed for in vivo
longitudinal monitoring of tumor growth, metastatic spread and therapeutic response. Preclinical
imaging therefore represents a useful tool for unravelling new imaging biomarkers for prediction and
evaluation of treatment response that eventually can be translated into the clinic [11]. Our research
group was, to our knowledge, the first to present a multimodal imaging set-up, similar to that routinely
employed at primary diagnostic work-up in the clinic, to monitor tumor growth in an orthotopic model
of EC [12]. This review will give an overview of available preclinical imaging modalities relevant for
gynecological cancers, in particular focusing on EC. Furthermore, we will highlight novel possibilities
for refined tumor characterization by emerging new functional imaging techniques and discuss some
of the challenges with preclinical imaging in EC.
2. Literature Search
The PubMed/Medline and Web of Science databases were searched for articles published up
to September 2019 with filtering for animal studies using the following terms and combinations
thereof: “endometrial cancer/carcinoma” or “uterine cancer” in combination with “imaging”, “magnetic
resonance imaging”, “positron emission tomography”, “single photon emission computed tomography”
“computed tomography”, “ultrasound”, “bioluminescence” and “fluorescence”. In addition, we also
searched the reference lists of selected studies and authors to identify additional relevant articles.
All studies recognized were assessed for relevance by checking the title and abstract. All irrelevant
articles, studies without access to the full text of the publication, non-English publications, letters and
proceedings were excluded.
3. Imaging in Endometrial Cancer
Imaging plays a central role in the management of EC patients. Although EC is formally
surgiopathologically staged according to the International Federation of Gynaecology and Obstetrics
(FIGO) staging system [13], preoperative imaging findings guide primary surgical treatment and
are especially useful to stratify high-risk patients for lymphadenectomy, which is a major clinical
challenge [14]. Although guidelines for state-of-the-art preoperative imaging in EC exist [15], differences
in access to advanced imaging facilities and dissimilar local preferences lead to variable practices across
centers. In humans, transvaginal ultrasound and/or magnetic resonance imaging (MRI) is typically
performed preoperatively to assess local tumor extent. Computed tomography (CT) alone or CT
combined with positron emission tomography (PET-CT) are useful to assess both abdominal spread
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to pelvic- and paraaortic lymph nodes as well as distant spread [16]. For EC animal models MRI,
PET-CT, CT and single-photon emission computed tomography (SPECT) have been used to depict
and monitor tumor growth. Furthermore, these imaging methods enable non-invasive evaluation
and quantification of treatment efficacy using novel therapies and depict imaging markers that are
closely linked to treatment response. Monitoring of preclinical EC tumor growth using ultrasound
could potentially also represent a valuable adjunct to these imaging modalities; however, we are not
aware of any preclinical EC studies using this method. Optical imaging using fluorescence can be used
to detect sentinel lymph nodes (SLN) in EC with high accuracy [17–20] and optical imaging using
fluorescence and bioluminescence has been widely used as an additional tool in preclinical EC studies.
3.1. MRI
MRI is a highly versatile modality with standard sequences yielding high soft-tissue resolution
providing detailed information on anatomy, and advanced imaging techniques allow depiction of
functional and microstructural properties of the tissue. Diffusion-weighted (DW)-MRI is a functional
imaging method depicting random diffusion of water molecules that reflects microstructural tissue
characteristics. Typically, malignant tumors exhibit higher cellular density which putatively induces
restricted water diffusion; thus, malignant tumors are often distinguished from normal tissue by its
restricted diffusion. The DW images using different diffusion weighting (b-values) are used to generate
apparent diffusion coefficient (ADC) maps on which the diffusion coefficient of the tissue can be
measured. Interestingly, changes in tumor ADC value, with normalization towards non-restricted
diffusion during treatment, have been linked to a favorable treatment response [21]. Dynamic
contrast-enhanced (DCE)-MRI is a different functional imaging method that depicts microvascular
features and yields imaging parameters reflecting tissue perfusion and permeability. For EC diagnosis,
conventional pelvic MRI is an excellent method to assess myometrial- and cervical stroma invasion [16],
and both DW- and DCE-MRI are considered promising supplementary MR sequences in EC for the
prediction of advanced stage and an aggressive clinical phenotype [22,23].
We have successfully imaged an orthotopic mouse model of EC using MRI, illustrating the
feasibility of anatomical MR sequences (T1 and T2-weighted) to depict tumor growth in the uterine
horns in mice [12]. Interestingly, the hyperintense tumor signal on T2-weighted series and the
hypointensity of the tumor (relative to the surrounding myometrium) on contrast-enhanced (CE)
T1-weighted series resemble that observed in human EC (Figure 1). Furthermore, the tumors in
mice also exhibit restricted diffusion on DW-MRI with hyperintensity on high b-value images and
corresponding low ADC value on the ADC map, being similar to that characteristically observed in
humans (Figure 1, Table 1) [12]. For further insight into characteristic imaging findings at conventional
imaging and novel promising imaging methods in human EC, we direct the readers to our recent
review [16].
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Figure 1. Axial magnetic resonance (MR) images depicting tumor (arrows) in an orthotopic endometrial cancer 
(EC) mouse model (Ishikawa cells) (A–D), and corresponding axial MRI images visualizing a uterine tumor 
(arrows) in an 87-year-old woman with EC (grade 2 endometroid, FIGO stage IIIC1; same patient as in Figure 2) 
(E–H). (A, E) T2-weighted images depict hyperintense tumors and (B, F) T1-weighted contrast-enhanced images 
(T1+c) depict moderately enhancing uterine tumors. (C, G) Both the preclinical- and human tumors exhibit 
restricted diffusion with hyperintensity on high b-value diffusion-weighted imaging (DWI) and (D, H) 
corresponding hypointensity on the apparent diffusion coefficient (ADC) maps. Images A–D are reproduced 
under the open access CC BY license from a previous publication [12]. 
3.2. PET 
PET imaging in oncology is most often performed using the 18F-labeled glucose, fluorodeoxyglucose 
(FDG). Malignant cells are metabolically characterized by elevated energy demands and will normally 
have an increased uptake of glucose. Cancers will therefore typically exhibit high uptake of FDG 
generating contrast in PET images. PET-CT can detect lymph node metastases in EC with high accuracy, 
thus preoperative FDG-PET imaging is often recommended in high-risk EC [27,28]. In addition to elevated 
FDG uptake in metastatic lymph nodes, primary EC are also typically highly FDG avid [27]. Increased 
FDG uptake in an orthotopic tumor model from both Ishikawa cells and from human endometrioid grade 
3 EC (PDX) has been demonstrated by our group using small-animal PET (Table 1) [12], and 
representative images illustrating the similar PET-CT findings observed in the PDX model and in human 
EC (endometroid grade 2, FIGO IIIC1) is shown in Figure 2. 
In a preclinical EC treatment study, it was recently shown that maximum standardized uptake 
values (SUVmax) decreased in lung metastases established from EC cell lines KLA and AN3CA by 
inhibiting the PI3K-pathway using ellagic acid (Table 1) [29]. 
Figure 1. Axial magnetic resonance (MR) images depicting tumor (arrows) i an orthotopic endometrial
cancer (EC) mouse model (Ishikawa cells) (A–D), a corresponding axial MRI images visualizing
a uterine tumor (arro s) in an 87-year-old woman with EC (grade 2 endometroid, FIGO stage IIIC1;
same patient as in Figure 2) (E–H). (A,E) T2-weighted images depict hyperintense tumors and (B,F)
T1-weighted contrast-enhanced images (T1+c) depict moderately enhancing uterine tumors. (C,G)
Both the preclinical- and human tumors exhibit restricted diffusion with hyperintensity on high b-value
diffusion-weighted imaging (DWI) and (D,H) corresponding hypointensity on the apparent diffusion
coefficient (ADC) maps. Images A–D are reproduced under the open access CC BY license from a
previous publication [12].
The loss of the phosphatase and tensin homolog (PTEN) is a frequent genetic aberration in EC [5],
and PTEN loss leads to alterations in the oncogenic PI3K signaling pathway and impaired homologous
recombination (HR) repair of DNA breaks [24]. In a treatment study, T2-weighted MRI was used
in a genetic mouse model of PTEN-deficient EC to show reduced tumor volume as a result of a
synergistic effect to combined treatment with PI3K- (BKM120) and poly (ADP-ribose) polymerase
(PARP) inhibitors (Olaparib) (Table 1) [25]. Similarly, T2-weighted MRI was used to show the tumor
size dependency on the mammalian target of rapamycin (mTOR) inhibitor rapamycin in a mouse
genetic model where EC developed after deletion of the tumor suppressor liver kinase 1B (Lkb1), a
negative regulator of the AMP-activated protein kinase (AMPK)-mTOR pathway (Table 1) [26].
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Figure 2. FDG PET-CT depicting an FDG-avid tumor in an orthotopic patient-derived xenograft (PDX) model of 
EC (grade 3 endometrioid) (A–C), and in an 87-year-old woman with EC (grade 2 endometroid, FIGO stage 
IIIC1; same patient as in Figure 1) (D–F). (A) In the mouse model, axial non-contrast CT imaging depicts a large 
tumor (t) (arrows) in the abdomen whereas (B) axial (C) and coronal FDG PET-CT display increased FDG uptake 
in the periphery of the tumor (arrows) and a central necrotic core (n). (D) In the patient, diagnostic contrast-
enhanced axial CT image depicts a slightly enhancing primary tumor (arrows) and (E) axial and (F) coronal FDG 
PET-CT depict an FDG-avid primary uterine tumor (arrow) and a metastatic parailiac lymph node (arrow). 
Physiologic FDG uptake in the heart (h), liver, kidneys, renal pelvis and intestines and urinary FDG excretion to 
the bladder (b) is visible. 
3.3. CT 
CT of the thorax, abdomen and pelvis is widely used to detect lymph node metastases and 
distant spread in EC patients [16]. In preclinical studies, CT has been used to detect both local and 
advanced disease. In an estrogen-controlled orthotopic model of EC using contrast-enhanced CT (CE-
CT), image-derived tumor volume was found to be positively correlated to tumor net weight at 
necroscopy (Table 1) [7]. CT was also used to detect lung metastases in a genetic mouse model where 
conditional inactivation of a downstream target of the transforming growth factor β (TGFβ) receptor, 
activin-like kinase 5 (Alk5), led to EC (Table 1) [30]. Furthermore, CT-assessed regression of lung 
metastases after ovariectomy indicated that the tumors were hormone-dependent [30]. 
3.4. SPECT 
SPECT is a nuclear medicine imaging technique based on the detection of gamma rays such as 
technetium-99 m (99mTc) and iodine-123 (123I). Clinically, SPECT-CT with 99mTc nanocolloid/tin colloid 
has been used preoperatively to identify SLN to stratify for lymphadenectomy in low-risk EC patients 
[19,31]. In preclinical EC models, SPECT has been used to monitor treatment efficacy of two different 
Figure 2. FDG PET-CT depicting an FDG-avid tumor in an orthotopic patient-derived xenograft (PDX)
model of EC (grade 3 endometrioid) (A–C), and in an 87-year-old woman with EC (grade 2 endometroid,
FIGO stage IIIC1; same patient as in Figure 1) (D–F). (A) In the mouse model, axial non-contrast CT
imaging depicts a large tumor (t) (arrows) in the abdomen whereas (B) axial (C) and coronal FDG
PET-CT display increased FDG uptake in the periphery of the tumor (arrows) and a central necrotic
core (n). (D) In the patient, diagnostic contrast-enhanced axial CT image depicts a slightly enhancing
primary tumor (arrows) and (E) axial and (F) coronal FDG PET-CT depict an FDG-avid primary uterine
tumor (arrow) and a metastatic parailiac lymph node (arrow). Physiologic FDG uptake in the heart (h),
liver, kidneys, renal pelvis and intestines and urinary FDG excretion to the bladder (b) is visible.
3.2. PET
PET imaging in oncology is most often performed using the 18F-labeled glucose, fluorodeoxyglucose
(FDG). Malignant cells are metabolically characterized by elevated energy dema ds and will normally
have an increased uptake of glucose. Cancers will therefore typically exhibit high uptake of FDG
generating contrast in PET images. PET-CT can detect ly ph node metastases in EC with high accuracy,
thus preoperative FDG-PET imaging is often recommended in high-risk EC [27,28]. In addition to elevated
FDG uptake in metastatic lymph nodes, primary EC are also typically highly FDG avid [27]. Increased
FDG uptake in an orthotopic tumor model from both Ishikawa cells and from human endometrioid
grade 3 EC (PDX) has been demonstrated by our group using small-animal PET (Table 1) [12], and
representative images illustrating the similar PET-CT findings observed in the PDX model and in human
EC (endometroid grade 2, FIGO IIIC1) is shown in Figure 2.
In a preclinical EC treatment study, it was recently shown that maximum standardized uptake
values (SUVmax) decreased in lung metastases established from EC cell lines KLA and AN3CA by
inhibiting the PI3K-pathway using ellagic acid (Table 1) [29].
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3.3. CT
CT of the thorax, abdomen and pelvis is widely used to detect lymph node metastases and distant
spread in EC patients [16]. In preclinical studies, CT has been used to detect both local and advanced
disease. In an estrogen-controlled orthotopic model of EC using contrast-enhanced CT (CE-CT),
image-derived tumor volume was found to be positively correlated to tumor net weight at necroscopy
(Table 1) [7]. CT was also used to detect lung metastases in a genetic mouse model where conditional
inactivation of a downstream target of the transforming growth factor β (TGFβ) receptor, activin-like
kinase 5 (Alk5), led to EC (Table 1) [30]. Furthermore, CT-assessed regression of lung metastases after
ovariectomy indicated that the tumors were hormone-dependent [30].
3.4. SPECT
SPECT is a nuclear medicine imaging technique based on the detection of gamma rays such
as technetium-99 m (99mTc) and iodine-123 (123I). Clinically, SPECT-CT with 99mTc nanocolloid/tin
colloid has been used preoperatively to identify SLN to stratify for lymphadenectomy in low-risk EC
patients [19,31]. In preclinical EC models, SPECT has been used to monitor treatment efficacy of two
different strains of oncolytic viruses (Copenhagen and Wyeth vaccinia virus) in subcutaneous AN3CA
and ARK-2 cell-line xenografts (Table 1) [32].
3.5. Optical Imaging
Optical imaging, which can be performed using bioluminescence (BLI) or fluorescence (FLI)
imaging techniques, is an excellent tool for visualization of tumor growth, metastases and treatment
effects in preclinical models. BLI requires transfection with luciferase-expressing reporter genes, and
as normal cells do not express luciferase, BLI provides excellent sensitivity for detecting tumor cells
and high signal-to-noise ratio [33,34]. Unfortunately, this also causes BLI to be ineligible for imaging of
PDX models, where genetic alteration of cells is unwarranted. In preclinical EC, BLI imaging has been
employed longitudinally to monitor tumor growth and metastatic spread [12,35] and to demonstrate
estrogen dependent tumor growth in orthotopic mouse models (Table 1) [7]. A representative BLI image
of a mouse orthotopically implanted with luciferase-expressing Hec1b tumor cells is shown together
with the corresponding necroscopy finding in Figure 3. In addition to visualizing tumor growth, BLI
can be used to monitor the activity of specific signaling pathways, including the identification of
significantly reduced activity in the NF-κB pathway following treatment with the heat shock protein
inhibitor NVP-AUY922 [36] (Table 1).
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dyes in humans, fluorescence-guided resection of primary tumor and metastatic lymph nodes in an 
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Figure 3. Bioluminescence imaging of an orthotopic EC mouse model. (A) Bioluminescence image and
(B) post-mortem examination of a female NSG mouse ten weeks post orthotopic implantation with
luciferase-expressing Hec1B cells. (D) Post-mortem examination revealed a primary uterine tumor and
(C) liver metastases corresponding to the bioluminescence signal.
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Fluorescent imaging (FLI) techniques are increasingly applied in preclinical research. Red
fluorescence generated by low doses of 5-aminolevulinic acid was recently demonstrated to allow
visualization of EC xenografts following ultrasound microbubble- and polyethyleneimine-mediated
knock-down of the enzyme ferrocheletase [37]. Furthermore, FLI using green fluorescent protein has
been employed to study the anti-tumor effect of the mTOR inhibitor rapamycin in EC models with
different PTEN expression levels. Rapamycin was found to more effectively inhibit tumor growth in
PTEN-negative EC tumors compared to PTEN-positive [38]. Similar to SLN-mapping using fluorescent
dyes in humans, fluorescence-guided resection of primary tumor and metastatic lymph nodes in an
orthotopic rabbit model of EC yielded overall good sensitivity and specificity overall [39].
Table 1. Preclinical imaging of endometrial cancer.
Imaging Modality/





findings using multiple imaging
techniques
Tumor can be delineated using
anatomic sequences and exhibits
restricted diffusion with low
ADC-values
Ishikawa cells, orthotopic, NSG
mice [12]
T2
Explore therapeutic effect of
combined PI3K (BKM120) and
PARP-inhibitor (Olaparib)
treatment







T2 Present a novel genetic mousemodel











CT-assessed tumor volume and





CT Present a novel genetic mousemodel
Detection of lung metastases
and regression of metastases
post-therapy (ovariectomy)







Growth of primary tumor and
metastases can be detected
Total lesion glycolysis was
calculated (SUVmean x MTV)
Ishikawa cells and PDX-model,
orthotopic, NSG mice [12]




Cell lines KLE and AN3CA





Explore effect of oncolytic
therapy
Tumor volume decreased after
therapy
Cell lines AN3CA and ARK-2,




of a mouse model
BLI signal increases over time.
Metastatic growth detected





BLI signal increases over time.
Metastatic growth detected






BLI signal increases in
estrogen-treated mice
Ishikawa cells, orthotopic,




activity in the NF-κB pathway
detected by BLI signal
Ishikawa cells, subcutaneous,
(unknown mice strain [36]
FLI Optimization of fluorescentsignal
Low dose ALA permits
detection of tumor by FLI
following knockdown of FECH
by ultrasound microbubbles and
polyethyleneimine
Hec1a cells, subcutaneous,
BALB/c- nude mice [37]
Investigate mTOR treatment in
tumors of different PTEN-status
(+/-)
Decreased GFP signal in PTEN-
compared to PTEN+ for
rapamycin-treated tumors





resection of tumor and
metastases
Detection and surgical removal
of fluorescent tumor tissue with
high sensitivity and specificity
VX2 rabbit tumor cells,
orthotopic, White New Zealand
rabbits
[39]
Abbreviations: ADC apparent diffusion coefficient, ALA 5-aminolevulinic acid, Alk5 activin-like kinase 5,
BLI bioluminescent imaging, CE contrast-enhanced, CT computed tomography, DW diffusion-weighted, FDG
fluorodeoxyglucose, FECH ferrocheletase, FLI fluorescence imaging, GFP green fluorescent protein, Hsp90 heat
shock protein 90, iv. intravenous, Lkb1 liver kinase b1, MRI magnetic resonance imaging, mTOR mammalian
target of rapamycin, MTV metabolic tumor volume, NF-κB nuclear factor kappa-light-chain-enhancer of activated B
cells, NSG NOD scid gamma mouse, PARP poly (ADP-ribose) polymerase, PDX patient-derived xenograft, PET
positron emission tomography, PTEN phosphatase and tensin homolog, SPECT single-photon emission computed
tomography, SUV standardized uptake value.
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4. Emerging Novel Imaging Techniques Relevant for Preclinical EC Models
Novel imaging methods and new tracers have the potential to yield clinically relevant cancer
biomarkers. Monitoring tumor growth in animal models using these imaging methods represents an
ideal research platform for testing and validation of cancer biomarkers prior to potential implementation
in the clinic. We will highlight promising and novel imaging techniques potentially relevant for
preclinical imaging of EC models using examples from breast and gynecologic cancers.
4.1. Radioligands for Visualization of Target-Specific Expression in EC
Targeted radioisotopes that bind to specific genetic alterations may identify subgroups of patients
that are likely to respond to corresponding targeted therapies, and may therefore serve as an imaging
method (using PET and SPECT) for treatment stratification in EC. Isotopes are summarized in Table 2.
Targeting of the human epidermal growth factor receptor-2 (HER2) is implemented in the treatment
of HER2-positive breast cancer, but is less studied for treatment of EC. We have recently shown that
high HER2 expression is associated with aggressive disease and poor survival in EC [41]. 89Zr-labeled
pertuzumab (89Zr-pertuzumab) has been used to detect HER2-positive breast cancer in small human
cohorts [42,43] and to delineate tumors and show treatment effects from trastuzumab-emtansine (T-DM1)
in HER2-positive breast cancer xenografts [44]. Similarly, PET-CT with radiolabeled pertuzumab
(64Cu-NOTA-pertuzumab) was used for non-invasive detection and monitoring of HER2 tumor
expression, enabling the detection of primary tumors and peritoneal metastases in both subcutaneous
and orthotopic models of ovarian cancer [45].
Cancer antigen 125 (CA125) is an important biomarker in clinical use for ovarian cancer; however,
CA125 has also been shown to predict lymph node metastases in EC [46]. A preclinical radiotracer
using 89Zr labeled mAb-B43.13 (89Zr-DFO-B43.13) to target CA125 expression by PET was recently
developed and validated in OVCAR3 ovarian xenografts [47], and this approach seems highly relevant
for future testing also in preclinical EC models.
It has been shown that tumor expression of epithelial membrane protein 2, EMP2 is associated
with aggressive disease in EC, and that EMP2 represents a novel biomarker for EC development [48,49].
Using radiolabeled antibody fragments of EMP2, 64Cu-DOTA-EMP2, this tracer was able to detect
tumor growth in a cell-line based Hec1a EC xenografts model in mice by PET [50].
The recently discovered G-protein coupled estrogen receptor (GPER) is expressed in tumors
where estrogen- and progesterone receptors are downregulated, and is associated with poor survival
in EC [51,52]. A 99mTc-labeled GPER ligand for use with SPECT was recently developed and validated
in EC Hec50 xenografts [53].
Table 2. Target-specific radiotracers relevant for endometrial cancer.






Uptake in human HER2+ breast
cancer [42,43] and mouse HER2+
xenografts (BT-474) including





High specificity to HER2 expression
and delineation of tumor and
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Table 2. Cont.






Delineation of subcutaneous ovarian
cancer xenografts (OVCAR3)[47].
GPER–SPECT




Uptake in subcutaneous EC (Hec50)
and breast cancer (MCF7/HER2–18)
xenografts [53].
Abbreviations: CA125 Cancer antigen 125, DFO desferrioxamine (chelating agent), DOTA
1,4,7,10-tetraazacyclododecane-N,N′,N′,N′”-tetraacetic acid (chelating agent), EMP2 epithelial membrane
protein-2, HER2 human epidermal growth factor-2, GPER G-protein coupled estrogen receptor, mAb monoclonal
antibody, NOTA 1,4,7-triazacyclononane-triacetic acid (chelating agent), T-DM1 trastuzumab-emtansine.
4.2. Oncologic PET Tracers Relevant for EC
A wide range of novel PET tracers are currently being developed with the aim of depicting
relevant biological processes and molecular targets in oncology, but presently there is little experience
with PET tracers beyond FDG in EC. We describe some of the more general radiotracers with potential
relevance for patient stratification and treatment assessment in EC. A summary is given in Table 3.
18F-labeled thymidine (FLT), is a PET tracer used to depict tissue with actively proliferating cells.
FLT is taken up and trapped intracellularly after phosphorylation by thymidine kinase 1 during the
S-phase of the cell cycle. Although not yet tested clinically for EC, we have demonstrated the feasibility
of FLT-PET to detect and monitor tumor growth in our EC mouse model [12]. For a number of different
tumors including animal models of breast- and ovarian cancers, FLT-PET has been used to evaluate
treatment response [54–60].
Unopposed estrogen stimulation is a central oncogenic mechanism driving the development of
the majority of ECs (type I; endometrioid) [61]. Furthermore, receptor status in EC provides prognostic
information, where loss of estrogen/progesterone receptor (ER/PR) predicts lymph node metastases and
poor survival [62]. Thus, PET using 18F-fluoroestradiol (FES), to non-invasively depict and quantify
whole-tumor expression of estrogen, has long been investigated for the clinical management of EC.
Interestingly, Tsujikawa et al. found that the FDG-to-FES SUV ratio is related to tumor aggressiveness
and that the more aggressive tumors depend less on estrogen and more on glucose metabolism.
Furthermore, tumor FES-PET avidity correlated well with ERα expression [63,64]. In a preclinical
study, FES-PET was used to detect early treatment response to the endocrine therapy fulvestrant in an
ER+ breast cancer xenograft model (MCF7), a response which was not detectable by FDG-PET [65].
Similarly, in ER+ breast xenografts (ZR-75-1) FES-PET could detect treatment response to fulvestrant,
whereas FDG- and 18F-fluoromisonidazole (FMISO; hypoxia tracer)-PET did not [66].
In general, hypoxia leads to a reduced response to chemo- and radiotherapy, and we have
shown that imaging and tissue markers for hypoxia predict reduced survival in EC [67]. Therefore,
detecting hypoxic tumors by preoperative functional imaging might have therapeutic consequences
and improve risk-stratification. Several PET tracers for hypoxia have been developed and FMISO
and 18F-fluoroazomycin-arabinofuranoside (FAZA) represent two of the most common commercially
available hypoxia tracers. Neither FAZA nor FMISO have been tested in preclinical or clinical EC, but
both have shown promise for detection of hypoxic regions in cervical cancer [68,69] and in animal
models of cervical and ovarian cancer [57,70,71].
4.3. Advanced MRI Sequences Relevant for EC
Advanced functional MRI sequences can be used to evaluate therapeutic response in cancer [21].
For preclinical gynecologic cancer models, but not yet for EC, DW- and DCE-MRI have been used to
assess therapeutic cellular and vascular response following targeted therapies. DW-MRI was used
to demonstrate treatment effects from perifosine, a PI3K-inhibitor, and the chemotherapeutic drug
cisplatin in a genetic model of ovarian cancer [72]. Furthermore, DW- and DCE-MRI was used for the
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non-invasive monitoring of treatment response during administration of the dual PI3K/mTOR-inhibitor
BEZ235 in two different subcutaneous ovarian cell-line xenograft models [73]. Rofstad and colleagues
have applied DCE-MRI to characterize hypoxia in the tumor microenvironment finding that low
values of the contrast agent transfer constant (Ktrans) is associated with areas of hypoxia, resistance to
radiotherapy and higher metastatic potential in cervical cancer models [74–76].
4.4. Advanced Image Analyses
One of the main advantages of the PET technology is the possibility to perform absolute
quantification – also in small animals. Clinically, PET images are usually acquired by conventional static
scanning, typically one hour post-injection for FDG-PET, and analyses are based on the semi-quantitative
and variation-prone parameter SUV [77]. In contrast, dynamic PET depicts the distribution of the
tracer in space and time from the time of injection, thus reflecting both the early uptake- and late
distribution phase and the metabolism. Pharmacokinetic modeling from dynamic imaging can
potentially yield functional tumor information beyond that represented by SUV and better characterize
tumor heterogeneity and monitor therapeutic response [78,79]. Interestingly, dynamic FDG-PET
using compartment modeling demonstrated treatment response from chemotherapeutics (doxorubicin,
paclitaxel and carboplatin) in three different breast cancer xenografts in mice, a response which was
not detectable using conventional SUV parameters [79].
Table 3. Novel imaging techniques relevant for clinical and preclinical imaging in endometrial cancer.
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Abbreviations: ADC apparent diffusion coefficient, DCE dynamic-contrast enhanced, DW diffusion-weighted, ERα
estrogen receptor α, FAZA fluoroazomycin-arabinofuranoside, FDG fluorodeoxyglucose, FLT fluorothymidine,
FMISO fluoromisonidazole, Ktrans volume transfer constant, MRI magnetic resonance imaging, mTOR mammalian
target of rapamycin, PET positron emission tomography, PI3K phosphoinositide 3-kinase, SUV standardized uptake
value, Ve extravascular extracellular space.
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5. Imaging-Related Challenges in Preclinical Endometrial Cancer Models
Primary gynecologic cancers are localized in the small pelvis in close proximity to the bladder
and the bowels; this often makes it challenging to distinguish tumor from surrounding, normal
tissues. As many PET tracers are excreted through the urinary track to the bladder; spill-over from
the bladder due to the partial volume effect (PVE) can affect the delineation of tracer avid tumor
tissue adjacent to the bladder and sometimes mask the entire tumor, especially in orthotopic mouse
models. Furthermore, physiologic FDG uptake in intestines and other abdominal organs can affect the
tumor segmentation even when fasting the mice prior to imaging (to reduce intestinal FDG uptake).
Similarly, FLT physiological uptake in proliferating tissues e.g., the intestines [12] and FMISO uptake
by anaerobic fecal bacteria [80] can complicate tumor segmentation.
For absolute quantification of dynamic PET or DCE-MRI images, the arterial input function (AIF)
is needed. To acquire AIF, the gold standard requires manual blood sampling at several time-points
after tracer/contrast agent injection. As the blood volume in small animals is very small (estimated
55–70 mL/kg body weight [81]), the method is technically challenging, subject to considerable variation
and does not allow for longitudinal studies. Several alternatives to derive the AIF exists, including
a pump-driven arteriovenous shunt connected to a coincidence counter (e.g., Twilite by Swisstrace),
a microfluidic chip blood-counting system [82] or indirect estimates based on the dynamic images
(image-derived input function, IDIF) or using a population-based input function (with or without
a blood sample for scaling). Which method that yields the most accurate quantification is however,
debated. Furthermore, the technical ease of the imaging procedure and the accumulated burden for
the animals undergoing sequential examinations are critical, if these practical interventional methods
are to be feasible for a broader use.
6. Conclusions
Detection and monitoring of tumor growth in preclinical EC models by using clinical imaging
methods such as CT, MRI, SPECT and PET is feasible. These dedicated small-animal imaging
technologies enable the identification of imaging biomarkers reflecting functional, microstructural and
metabolic tumor features relevant for EC phenotype. The majority of preclinical studies exploring
new targeted therapies with potential for personalizing EC treatment, still rely on endpoint volumetric
measurements of tumor size. The therapeutic effect of molecularly targeted drugs not having an
immediate effect on tumor size may consequently be overlooked. However, novel functional imaging
techniques and new tracers enable quantification and depiction of molecularly targetable pathogenic
mechanisms, yielding information beyond what has previously been obtainable. However, the
development of relevant target-specific imaging biomarkers in EC is still in its infancy, and new
imaging techniques and tracers are likely to be developed in the near future. Furthermore, all
promising imaging techniques will require careful validation and clinical testing prior to potential
translation into the clinic. Importantly, imaging biomarkers identified by preclinical models with
subsequent validation in clinical patient series, are likely to play a central role in future developments
of new targeted treatment strategies in gynecologic cancer.
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